Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06667272 · 1 trial · 1 indication
Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.
| Arm | Type | Description |
|---|---|---|
| Cohort 1_Period 1_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 1_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 1_Period 2_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 2_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 1_Period 3_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 3_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohrot 1_Period 4_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 4_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 1_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 1_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 2_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 2_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 3_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 3_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 4_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 4_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Name | Type | Description |
|---|---|---|
| PF-06667272 | DRUG | Single ascending dose of PF-06667272 |
| Placebo | OTHER | Single dose of placebo |
Inclusion Criteria: * Healthy males and female of non-childbearing potential; * Body Mass Index 17.5-30.5 kg/m2; * Body weight \>50 kg; Exclusion Criteria: * Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychi...
PF-06667272 is an investigational small molecule developed by Pfizer, Inc. It has been studied in a first-in-human Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
PF-06667272 is made by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the developer responsible for the clinical program evaluating this small molecule.
PF-06667272 is in Phase 1 development. Its only recorded clinical trial, a first-in-human study, has been completed. The drug remains investigational and has not been approved by the FDA for any indication.
PF-06667272 has been evaluated in one clinical trial, NCT03126149, titled First in Human Study for PF-06667272. The Phase 1 trial enrolled 16 healthy adult volunteers in Belgium, was randomized, double-blind, and placebo-controlled, and is now completed.
PF-06667272 has been studied in healthy volunteers rather than in patients with a specific disease, and the targeted indication has not been disclosed. Its completed Phase 1 trial, NCT03126149, assessed the drug in healthy adults in Belgium.